Bristol-Myers Squibb Company
์๊ฐ์ด์ก
$125.6B
๊ธ๋ก๋ฒ ์์
#132
์ญ๋ ์ต๊ณ ์น
$139.1B
2026-09-03
์ด ์ฑ์ฅ๋ฅ
+0%
2026๋ ์ดํ
Market Cap Context
- Larger than 64% of the 367 companies we track (globally).
- Equivalent to 0.4% of United States's GDP (2025 data).
- Just above: #131 ๋ ธ๋ณด ๋ ธ๋์คํฌ ($125.9B)
- Just below: #133 Altria Group, Inc. ($124.1B)
- Best year: 1997 (+78%). Worst year: 2002 (-53%).
Bristol-Myers Squibb Company Financial Breakdown (FY 2025)
Source: Yahoo Finance โ BMY annual filings (2025) โ$48.2B revenue ยท $13.7B operating income ยท $7.1B net income
- โOperating margin: 28.5% on $48.2B in revenue.
- โR&D is 20.6% of revenue ($10.0B).
- โNet income margin: 14.6% โ $7.1B in profit.
- โFree cash flow: $12.8B (26.7% of revenue).
Cost / Operating Expenses
Total operating expenses $34.5B
Total
$31.2B
Capital Expenditures
$1.3B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$12.8B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Bristol-Myers Squibb Company ์๊ฐ
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Bristol-Myers Squibb Company ์๊ฐ์ด์ก ์ถ์ด (2026โ2026)
Bristol-Myers Squibb Company vs Sector Peers by Market Cap
Bristol-Myers Squibb Company ๋น๊ต
์์ ์ถ์ด
| ์ฐ๋ | ์๊ฐ์ด์ก | ์์ | ์ ๋ ๋๋น ๋ณํ |
|---|---|---|---|
| 2026 | $125.6B | #132(โ7) | +16.6% |
| 2025 | $107.8B | #139(โ15) | +0.1% |
| 2024 | $107.6B | #124(โ3) | +15.8% |
| 2023 | $92.9B | #121(โ53) | -26.1% |
| 2022 | $125.8B | #68(โ26) | +19.0% |
| 2021 | $105.8B | #94(โ13) | +3.7% |
| 2020 | $102.0B | #81(โ14) | -0.4% |
| 2019 | $102.4B | #67(โ6) | +27.7% |
| 2018 | $80.2B | #61(โ9) | -12.9% |
| 2017 | $92.0B | #52(โ6) | +7.7% |
| 2016 | $85.4B | #46(โ17) | -13.0% |
| 2015 | $98.2B | #29(โ11) | +19.3% |
| 2014 | $82.3B | #40(โ2) | +14.2% |
| 2013 | $72.0B | #42(โ16) | +68.8% |
| 2012 | $42.7B | #58(โ15) | -3.8% |
| 2011 | $44.4B | #43(โ24) | +39.4% |
| 2010 | $31.8B | #67 | +10.1% |
| 2009 | $28.9B | #67(โ14) | +15.0% |
| 2008 | $25.1B | #53(โ28) | -7.3% |
| 2007 | $27.1B | #81(โ13) | +4.8% |
| 2006 | $25.9B | #68(โ4) | +19.9% |
| 2005 | $21.6B | #72(โ11) | -6.1% |
| 2004 | $23.0B | #61(โ15) | -6.3% |
| 2003 | $24.5B | #46(โ3) | +29.4% |
| 2002 | $19.0B | #43(โ18) | -53.0% |
| 2001 | $40.3B | #25(โ4) | -26.2% |
| 2000 | $54.6B | #21(โ4) | +17.1% |
| 1999 | $46.6B | #25(โ8) | -2.8% |
| 1998 | $48.0B | #17(โ2) | +43.6% |
| 1997 | $33.4B | #19(โ9) | +77.5% |
| 1996 | $18.8B | #28(โ2) | +31.2% |
| 1995 | $14.3B | #26(โ1) | +55.2% |
| 1994 | $9.2B | #25 |
๊ธฐํ ํฌ์ค์ผ์ด ๊ธฐ์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company (BMY) has a market capitalization of $125.6B, making it the #132 largest company in the world by market cap.
What was Bristol-Myers Squibb Company's highest market cap?
Bristol-Myers Squibb Company's all-time high market cap was $139.1B, reached in 2026-09-03. Its highest rank was #68 in 2022.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.
How has Bristol-Myers Squibb Company's market cap changed over time?
Bristol-Myers Squibb Company has been tracked since 2026. Its market cap has grown by 0% from $125.6B in 2026 to $125.6B today.